Definium Therapeutics (DFTX) Net Cash Flow (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Net Cash Flow of $4.7 million for Q1 2026, up 102.45% year-over-year from $2.3 million in Q1 2025, and down 98.03% quarter-over-quarter from $237.9 million in Q4 2025.
Definium Therapeutics (DFTX) Net Cash Flow (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Net Cash Flow for 6 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 102.45% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $179.7 million (up 206.02% YoY), while the FY2025 annual figure was -$15.9 million, down 109.13% from the prior year.
- Net Cash Flow retreated to $4.7 million in Q1 2026 per DFTX's latest filing, from $237.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $237.9 million in Q4 2025 and bottomed at -$190.9 million in Q1 2025.
- Historically, Net Cash Flow has averaged $7.6 million across 5 years, with a median of -$12.6 million in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow soared 6656.87% — and 2025, when it sank 437.84%.
- Definium Therapeutics' Net Cash Flow stood at -$12.4 million in 2022, then tumbled by 44.53% to -$18.0 million in 2023, then dropped by 19.89% to -$21.5 million in 2024, then surged by 1204.15% to $237.9 million in 2025, then plunged by 98.03% to $4.7 million in 2026.
- Business Quant data shows DFTX's Net Cash Flow at $4.7 million in Q1 2026, $237.9 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | 392.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 392.75 Mn |
| Jun 30, 2026 | 392.75 Mn |
| Mar 31, 2026 | 4.68 Mn |
| Mar 31, 2026 | 4.68 Mn |
| Dec 31, 2025 | 237.88 Mn |
| Dec 31, 2025 | 237.88 Mn |
| Sep 30, 2025 | -13.41 Mn |
| Sep 30, 2025 | -13.41 Mn |
| Jun 30, 2025 | -49.49 Mn |
| Jun 30, 2025 | -49.49 Mn |
| Mar 31, 2025 | -190.88 Mn |
| Mar 31, 2025 | -190.88 Mn |
| Dec 31, 2024 | -21.54 Mn |
| Dec 31, 2024 | -21.54 Mn |
| Sep 30, 2024 | 52.16 Mn |
| Sep 30, 2024 | 52.16 Mn |
| Jun 30, 2024 | -9.20 Mn |
| Jun 30, 2024 | -9.20 Mn |
| Mar 31, 2024 | 152.65 Mn |
| Mar 31, 2024 | 152.65 Mn |